merckGermany's Affectis Pharmaceuticals will pocket a €2.4 million upfront along with additional research funds from Merck Serono for a pact to develop and commercialize oral drugs targeting P2X7 receptors, which are believed to be involved in neuroinflammation observed in some neurodegenerative diseases. Affectis could garner up to €277 million for the first three approved products. ReleasNow that Grifols has completed its $4 billion acquisition of Talecris, CEO Victor Grifols Roura says he expects that job cuts will be limited to less than 5% of Talecris's 8,500 U.S. employees. Report.
The companies said the recommendation was made based upon both the observation that V710 was “unlikely to demonstrate a statistically significant clinical benefit as well as a safety concern regarding overall mortality and multi-organ dysfunction that occurred with greater frequency in vaccine recipients, compared with placebo recipients.” In the additional analyses that were performed, the companies said, this safety difference was not found to be statistically significant and was also determined not to warrant any action beyond a routine safety follow-up.
No comments:
Post a Comment